Clinical Trials Logo

Alopecia Areata clinical trials

View clinical trials related to Alopecia Areata.

Filter by:

NCT ID: NCT05017454 Completed - Alopecia Areata Clinical Trials

Sodium Valproate-loaded Nanospanlastics in Patchy Alopecia Areata in Comparison to Topical Steroids

Start date: May 1, 2021
Phase: Early Phase 1
Study type: Interventional

the aim of this study is to assess the efficacy and safety of sodium valproate-loaded nanospanlastic in the treatment of patchy AA, in comparison to conventional therapy with topical steroids

NCT ID: NCT04984707 Completed - Clinical trials for Androgenetic Alopecia

Safety, Tolerability and Pharmacokinetics of KX826 in Healthy Male Subjects With Androgenetic Alopecia Following Topical Single Ascending Dose Administration

Start date: January 28, 2019
Phase: Phase 1
Study type: Interventional

The study is a Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Escalation Study in Healthy Male Subjects with Androgenetic Alopecia to Evaluate the Safety, Tolerability and Pharmacokinetics of KX-826 Following Topical Single Ascending Dose Administration

NCT ID: NCT04964349 Recruiting - Alopecia Areata Clinical Trials

Efficacy of Jessener Solution Versus Intralesional Steroid in Treatment of Alopecia Areata

AA
Start date: April 21, 2021
Phase: Early Phase 1
Study type: Interventional

Alopecia areata is believed to be an autoimmune disease. Treatment primarily relies on intralesional and topical corticosteroids. This study was conducted to evaluate Jessener Solutionas a potential therapeutic modality of Alopecia Areataversusintralesional steroid as regards the efficacy, safety, tolerability, and patients' satisfaction.

NCT ID: NCT04913519 Completed - Clinical trials for Alopecia, Androgenetic

A Phase 1 Study of TDM-105795 Topical Solution in Male Subjects With Androgenetic Alopecia (AGA)

AGA
Start date: April 27, 2021
Phase: Phase 1
Study type: Interventional

Multi-center, fixed volume, randomized, double-blind, vehicle-controlled, parallel group, dose escalation comparison study of TDM-105795 in male subjects, 18 to 55 years old, with Androgenetic Alopecia (AGA).

NCT ID: NCT04898166 Completed - Covid19 Clinical Trials

Association of Androgenetic Alopecia and Severity of Coronavirus Disease 2019 (COVID-19).

Start date: December 1, 2020
Phase:
Study type: Observational [Patient Registry]

Coronavirus disease 2019 (COVID-19) can cause variable symptoms ranging from mild common cold-like symptoms to severe life threatening pneumonia. Recent studies show severe outcomes of COVID-19 patients specially in males who suffer from androgenetic alopecia, would be significant and is of particular interest of this study and could help further support the hypothesis that anti-androgen therapy might represents an additional potential intervention against severe COVID-19.

NCT ID: NCT04897555 Completed - Alopecia Clinical Trials

LLLT for Alopecia of the Eyebrow in Women

Start date: May 1, 2019
Phase: N/A
Study type: Interventional

The purpose of this research is to study the ongoing effectiveness of a light therapy device for human hair growth. This device, called the iRestore Eyebrow Device, is a type of cold, or non-heat producing light therapy system that will emit light on the hair growth cells within and around the hair follicle. When these cells do not function properly, one may experience common problems such as baldness and thinning or brittle hair. The application of a special category of low-level light to be studied in the project may cause an increase in essential nutrients to the damaged hair follicles and skin cells, leading to a reduction in hair loss and in some cases, possibly leading to re-growth.

NCT ID: NCT04884347 Completed - Hair Loss Clinical Trials

Evaluation of the Efficacy of a Food Supplement in Reducing Hair Loss in Male Subjects

Start date: August 31, 2020
Phase: N/A
Study type: Interventional

According to the American Hair Loss Association, by the age of 35, two-thirds of American men will have some degree of appreciable hair loss, and by the age of 50, approximately 50 to 85% of men will have significant hair thinning. Hair is an essential aspect of human appearance and can have a significant impact on a person's self-esteem, mood and quality of life. Unfortunately, current treatment options can be costly, tedious or painful. They are also associated with numerous side effects. Here, the investigators aimed at evaluating the effect of a new food supplement on hair condition in young men suffering from hair loss. A second goal was to determine tolerability.

NCT ID: NCT04882969 Withdrawn - Clinical trials for Androgenetic Alopecia

Thulium Laser and KeraFactor for the Treatment of Androgenetic Alopecia

Start date: September 1, 2021
Phase: N/A
Study type: Interventional

The objective of this clinical study is to assess the safety and efficacy of using a laser and hair growth factors in the treatment of male-pattern hair loss. Participating subjects will receive up to two (2) treatments per month for 6 months with the laser and post-treatment topically applied hair growth factors and will have a 6 month follow-up period.

NCT ID: NCT04880889 Not yet recruiting - Telogen Effluvium Clinical Trials

BL3000 Compared to Pantogar® in the Treatment of Telogen Effluvium in Women.

Start date: January 1, 2023
Phase: Phase 3
Study type: Interventional

Study phase III, randomized, double-dummy, placebo controlled, single-center, of regarding the non-inferiority of the medication BL3000, when compared to Pantogar® treatment of telogen effluvium in women. Research product: BL3000. Reference product: Pantogar® List of Study Center: MAIN INVESTIGATOR STUDY CENTER FONE Medcin Skin Institute Sérgio Schalka 11 36835357

NCT ID: NCT04842383 Recruiting - Clinical trials for Androgenetic Alopecia

Androgenetic Alopecia Treatment Using Varin and Cannabidiol Rich Topical Hemp Oil: A Case Series

Hair Regrowth
Start date: April 5, 2021
Phase: Early Phase 1
Study type: Interventional

This is a case series of adult, male and female subjects with androgenetic alopecia (male pattern baldness). A topical hemp oil that is rich in varins (THCV and CBDV) and cannabidiol (CBD) is being used daily for six months to stimulate hair regrowth using Endocannabinoid System (ECS) receptors that are found on hair follicles.